Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein

Interim results from the Guinea ring vaccination cluster-randomised trial

From:
Foreign, Commonwealth & Development Office
Published
1 August 2015
Country:
Guinea
Document Type:
Journal Article
Theme:
Health
Authors:
Henao-Restrepo, A.M.

Abstract

A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.

Citation

Ana Maria Henao-Restrepo, Ira M Longini, Matthias Egger, Natalie E Dean, W John Edmunds, Anton Camacho, Miles W Carroll, Moussa Doumbia, Bertrand Draguez, Sophie Duraffour, Godwin Enwere, Rebecca Grais, Stephan Gunther, Stefanie Hossmann, Mandy Kader Kondé, Souleymane Kone, Eeva Kuisma, Myron M Levine, Sema Mandal, Gunnstein Norheim, Ximena Riveros, Aboubacar Soumah, Sven Trelle, Andrea S Vicari, Conall H Watson, Sakoba Kéïta, Marie Paule Kieny, John-Arne Røttingen. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet, Volume 386, Issue 9996, 2015, Pages 857-866. https://doi.org/10.1016/S0140-6736(15)61117-5.

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination cluster-randomised trial

Published 1 August 2015
Contents